Why there is no price
A medicine gets a list price when it is approved and launched. Retatrutide has not been approved anywhere, and Lilly states that anyone selling it to consumers is breaking the law.[1] Any price you see online is for an unapproved, unregulated product.
For context: what Lilly charges for Zepbound
The closest reference is tirzepatide (Zepbound), Lilly's approved weight-loss drug. These are Lilly's own self-pay prices on LillyDirect, checked on November 13, 2026:[2]
| Dose | Single-dose vials or KwikPen, per 4-week supply |
|---|---|
| 2.5 mg | $299 |
| 5 mg | $399 |
| 7.5 mg | $449 if refilled within 45 days, otherwise $499 |
| 10–15 mg | $449 if refilled within 45 days, otherwise $699 |
These prices say nothing certain about what retatrutide will cost. Lilly has not announced a price or a pricing approach for it.
Two details from the same LillyDirect page show how pricing for these drugs is structured. Single-dose pens are listed for insured patients, "as low as $25" a month with commercial coverage. The self-pay vials are priced per 4-week supply of four weekly doses, so the 2.5 mg tier works out to about $75 per weekly dose.[2]
Retatrutide price per month
No legitimate retatrutide price per month exists in November 2026. Lilly has not announced a list price, a self-pay price or an insurance plan, and it cannot do so before approval.[1] Its planned U.S. submission is in the first quarter of 2027.[8]
| Route | Monthly price | Source |
|---|---|---|
| Approved prescription | None: not approved | Lilly, October 2026[1] |
| Clinical trial | Not a purchase; set by the study | ClinicalTrials.gov[5] |
| Early access (expanded access) | Not disclosed | ClinicalTrials.gov record and Lilly statement[6][7] |
| Online "research" sellers | Not a legal price; illegal sale | Lilly, FDA[1][3] |
Retatrutide is given once a week, so a month of treatment would be four or five doses. For comparison only, Zepbound's self-pay vials are priced per four weekly doses, as shown above.[2]
Will retatrutide come as a pen?
Lilly has not announced how retatrutide would be sold. A completed phase 1 study (NCT06003465) compared versions of the drug for different injection devices, which is a normal step before launch.[5] Lilly sells its approved drug Zepbound both as pens and as single-dose vials, at different prices.[2] Any "retatrutide pen" sold online today is not Lilly's product.
What would decide the price
- Approval first. Lilly plans to submit retatrutide to the FDA in the first quarter of 2027. No price can exist before an approval decision. See FDA approval status.[1]
- The approved doses. Phase 3 trials used 4, 9 and 12 mg maintenance doses. Tirzepatide's self-pay price rises with dose, as the table above shows. See the retatrutide dosage chart.
- Pens or vials. Zepbound is sold both ways, at different price points and with different insurance rules.[2]
The only legitimate ways to get it today
Before approval, retatrutide is available only to people enrolled in a clinical trial, or through a physician-requested single-patient expanded-access program. That program is limited to people with a BMI of 35 or more, at least two serious obesity complications, no response to approved treatments, and no access to a trial.[5] Neither route involves buying the drug. Both are explained on how to get retatrutide.
Why cheap online offers are a warning sign
- The FDA has warned sellers of products labeled "research use only" that were in fact sold to consumers for human use with dosing instructions.[3]
- In August 2026 Lilly asked online platforms, payment companies and regulators to shut down what it called "the illegal retatrutide black market".[4]
- Products outside the regulated supply chain are not checked for identity, strength or sterility.
More detail: "research use" retatrutide and the FDA.
Frequently asked questions
Will insurance cover retatrutide?
Coverage cannot be known until the drug is approved and priced. Coverage of approved weight-loss drugs varies widely by plan.
How much does Zepbound cost without insurance?
On LillyDirect, Zepbound vials and KwikPens cost $299 (2.5 mg) or $399 (5 mg) per 4-week supply, and $449–$699 for higher doses depending on refill timing.[2]
Is cheap retatrutide online real?
Will retatrutide cost more than Zepbound?
Nobody knows yet. Lilly has not said how it will price retatrutide, and the price can only be set after approval. Comparisons with Zepbound give context, not a forecast. The trial data the FDA will review are summarized on the results page.
Sources
- Lilly: retatrutide vs semaglutide 2 mg in TRANSCEND-T2D-2
- Zepbound self-pay pricing on LillyDirect
- FDA's concerns with unapproved GLP-1 drugs used for weight loss
- Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market
- Retatrutide studies (NCT04881760, NCT05929066, NCT05931367, NCT06662383, NCT07629401 and others)
- Pre-approval expanded access of retatrutide (LY3437943), NCT07629401
- Eli Lilly to offer early access to next-gen obesity drug to some patients
- Lilly: retatrutide successful in two additional phase 3 obesity trials (TRIUMPH-2, TRIUMPH-3)